Abstract
Background: Bibliometric analyses are used to provide information on trends within a specific research field, along with indicators of the impact of a publication. With such an analysis, we map the scientific landscape of chimeric antigen receptor T-cell (CAR-T) research to see the emerging topics and infer directions the field might take.Methods: We extracted the 100 most-cited articles, published all periods (from 2008 to 2019) by the Web of Science Core Collection. Using their bibliographic details, including year of publication, country of author, research organization, author information, and keywords, we graph the networks created between the articles.Results: Of the 100 papers identified, the majority (93%) were written in the USA. Notable was that 34 papers were published from the University of Pennsylvania. Regarding authors, Carl H. June participated in 29 researches, followed by Bruce L. Levine who participated in 12. As for journals, Blood (n = 19) published the most papers, followed by Science Translational Medicine (n = 9) and Cancer Research (n = 9). Lastly, the most frequently used keywords were “adoptive immunotherapy” (n = 47), “lymphocytes” (n = 27), and “antitumor activity” (n = 22).Conclusion: By evaluating the top 100 most-cited papers in the CAR-T field, this study provides insight into the direction of the scientific growth and its trends, as well as information on the field's network structure.
Highlights
Since chimeric antigen receptors (CARs) were genetically engineered to express on T-cells three decades ago [1], they have become one of the most promising targeted immunotherapy research interests
Novartis CARa -T 4-1BB CS B-ALLb: ELINA/DLBCLc: JULIET Approved by USFDA $475,000 for B-ALL; $373,000 for R/Rd DLBCL B-ALL, R/R DLBCL Patient PBMCse; autologous; unspecified Lentivirus B-ALL = 63, R/R DLBCL = 93 B-ALL = ND, DLBCL = 52% B-ALL = 83%, DLBCL = 40% B-ALL = 20%, DLBCL = 12% B-ALL = NR, DLBCL = 11.7 months aCAR, chimeric antigen receptor. bB-ALL, B-cell acute lymphoblastic leukemia. cDLBCL, diffuse large B-cell lymphoma. dR/R, relapsed or refractory. ePBMC, peripheral blood mononuclear cells. f CD, cluster of differentiation. gPMBCL, primary mediastinal large B-cell lymphoma. hNA, not applicable. iCLL, chronic lymphocytic leukemia. jMM, multiple myeloma
Gilead (Kite) CAR-T CDf28 CS TOWER Approved by USFDA $373,000
Summary
Since chimeric antigen receptors (CARs) were genetically engineered to express on T-cells three decades ago [1], they have become one of the most promising targeted immunotherapy research interests. These CAR T-cells (CAR-Ts) are modified to express cancer antigen-recognizing CARs and to stimulate the immune system [2,3,4]. Bibliometric analyses are used to provide information on trends within a specific research field, along with indicators of the impact of a publication With such an analysis, we map the scientific landscape of chimeric antigen receptor T-cell (CAR-T) research to see the emerging topics and infer directions the field might take
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
